Success Metrics

Clinical Success Rate
90.0%

Based on 108 completed trials

Completion Rate
90%(108/120)
Active Trials
8(5%)
Results Posted
50%(54 trials)
Terminated
12(8%)

Phase Distribution

Ph phase_1
33
22%
Ph phase_2
30
20%
Ph phase_3
21
14%
Ph not_applicable
18
12%
Ph phase_4
38
26%
Ph early_phase_1
4
3%

Phase Distribution

37

Early Stage

30

Mid Stage

59

Late Stage

Phase Distribution144 total trials
Early Phase 1First-in-human
4(2.8%)
Phase 1Safety & dosage
33(22.9%)
Phase 2Efficacy & side effects
30(20.8%)
Phase 3Large-scale testing
21(14.6%)
Phase 4Post-market surveillance
38(26.4%)
N/ANon-phased studies
18(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.0%

108 of 127 finished

Non-Completion Rate

15.0%

19 ended early

Currently Active

8

trials recruiting

Total Trials

149

all time

Status Distribution
Active(8)
Completed(108)
Terminated(19)
Other(14)

Detailed Status

Completed108
unknown14
Terminated12
Recruiting7
Withdrawn7
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
149
Active
8
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (2.8%)
Phase 133 (22.9%)
Phase 230 (20.8%)
Phase 321 (14.6%)
Phase 438 (26.4%)
N/A18 (12.5%)

Trials by Status

active_not_recruiting11%
recruiting75%
unknown149%
completed10872%
terminated128%
withdrawn75%

Recent Activity

Clinical Trials (149)

Showing 20 of 149 trialsScroll for more
NCT05646862Phase 3

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Active Not Recruiting
NCT01789710Not Applicable

Contingency Management for Smoking Cessation in Homeless Smokers

Completed
NCT03511118

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Recruiting
NCT06679413Phase 1

A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants

Completed
NCT07223671Phase 1

Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants

Completed
NCT06564441Phase 1

A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity

Completed
NCT05732272Phase 3

Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment

Recruiting
NCT07235748Phase 1

Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants

Completed
NCT05205811Phase 3

The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette

Completed
NCT04634071Phase 2

Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment

Completed
NCT05603104Phase 3

Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

Recruiting
NCT03227679Not Applicable

Metabolism-informed Care for Smoking Cessation

Completed
NCT04422652Phase 2

Combination of Novel Therapies for CKD Comorbid Depression

Recruiting
NCT03978442Phase 4

CPT-SMART for Treatment of PTSD and Cigarette Smoking

Completed
NCT05973786Phase 3

The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Recruiting
NCT06374290Phase 1

Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia

Terminated
NCT05537584Phase 4

SMART Trial to Predict Anhedonia Response to Antidepressant Treatment

Completed
NCT03950427Phase 4

PARQuit Smoking Cessation Intervention for Adults With Serious Mental Illness

Completed
NCT06973005Phase 1

A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants

Completed
NCT05351606Phase 4

Integrating Tobacco Use Cessation Into HIV Care and Treatment in Kisumu County, Kenya

Completed

Drug Details

Intervention Type
DRUG
Total Trials
149